Status:

COMPLETED

Antithrombotic Regimens and Outcome

Lead Sponsor:

Careggi Hospital

Conditions:

Coronary Artery Disease

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

PROTOCOL SYNOPSIS Title: Comparison of bivalirudin and unfractioned heparin (UFH)+ protamine in elective percutaneous coronary interventions (PCI) Design: Prospective, randomized, controlled trial H...

Detailed Description

Bivalirudin, a direct thrombin inhibitor, has been recently introduced as an alternative to UFH given several important biologic and pharmacokinetic advantages.1,2 In contrast to UFH, it acts independ...

Eligibility Criteria

Inclusion

  • Patients older than age 18 to undergo PCI
  • Pretreatment at least 6 hours before PCI with clopidogrel according to the PCI guidelines.
  • Informed, written consent by the patient or her/his legally-authorized representative for participation in the study.

Exclusion

  • Recent ST-elevation myocardial infarction within the last 48 hours.
  • Chronic coronary artery occlusion to be treated
  • Malignancies or other comorbid conditions (for example severe liver, renal and pancreatic disease) with life expectancy less than one year or that may result in protocol non-compliance.
  • Active bleeding, bleeding diathesis, recent surgery (\< 15 days)
  • History of gastrointestinal or genitourinary bleeding within the last 6 weeks
  • Treatment with UFH within 6 hours or low-molecular weight heparin within 8 hours before randomization.
  • Treatment with bivalirudin within 24 hours beforerandomization.
  • Severe uncontrolled hypertension \>180/110 mmHg unresponsive to therapy
  • Relevant hematologic deviations: hemoglobin \< 100 g/L OR platelet count \< 100 x 109 /L.
  • Glomerular filtration rate (GFR) \< 30 ml/min or serum creatinine \> 30 mg/L or dependence on renal dialysis.
  • Known allergy to the study medications: aspirin, clopidogrel, UFH, bivalirudin; stainless steel; true anaphylaxis after prior exposure to contrast media.
  • Known heparin-induced thrombocytopenia

Key Trial Info

Start Date :

March 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2008

Estimated Enrollment :

850 Patients enrolled

Trial Details

Trial ID

NCT00448461

Start Date

March 1 2007

End Date

June 1 2008

Last Update

February 10 2009

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Division of Cardiology, Careggi Hospital

Florence, Italy, 50141